Cancer-Fighting virus shows promise in Hard-to-Treat ovarian cancer
NCT ID NCT02759588
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new immunotherapy called Olvi-Vec, which uses a modified virus to attack cancer cells, in 46 patients with ovarian cancer that had come back or stopped responding to standard treatments. The goal was to see if the treatment was safe and could slow tumor growth. Results focused on side effects and how long patients lived without their cancer getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Cancer Institute
Orlando, Florida, 32804, United States
-
Gynecologic Oncology Associates
Newport Beach, California, 92663, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Lab-Grown tumor models predict the best therapy for each patient?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?